Advertisement

Journal of Neurology

, Volume 258, Issue 5, pp 946–947 | Cite as

Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration

  • J. Schessl
  • M. Schuberth
  • P. Reilich
  • P. Schneiderat
  • N. Strigl-Pill
  • M. C. Walter
  • B. Schlotter-Weigel
  • B. Schoser
Letter to the Editors

Dear Sirs,

Paraneoplastic cerebellar degeneration (PCD) is a rare heterogeneous group of disorders associated with cancer and anti-neuronal antibodies. Patients display symptoms reflecting cerebellar dysfunction including dysarthria, severe ataxia and abnormal oculomotor functions. Anti-Yo antibodies, also often called Purkinje cell antibodies type 1 (PCA-1), occur in patients with PCD having a history of tumors of the ovary, endometrium, fallopian tube or breast cancer [6, 11]. The treatment of PCD associated with anti-Yo antibodies is very limited and does usually not respond to immunosuppressive or tumor therapy. We report improvement and stabilization in a patient with an anti-Yo syndrome with PCD secondary to ovarian carcinoma through 10 years of treatment with intravenous immunoglobuline (IVIG).

A 72-year-old female patient was diagnosed with an ovarian carcinoma with TNM-classification pT3, pN1, G3 at the age of 61 years. The patient subsequently underwent surgery followed by...

Keywords

Purkinje Cell Ovarian Carcinoma Cerebellar Ataxia IVIG Treatment Spontaneous Nystagmus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We would like to thank the patient reported here for her participation and encouragement. J.S., P.R., P.S., M.C.W. and B.S. are members of the German network on muscular dystrophies (MD-NET) funded by the German Ministry of Education and Research (BMBF, Bonn, Germany).

References

  1. 1.
    Batchelor TT, Platten M, Hochberg FH (1998) Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 40:131–136PubMedCrossRefGoogle Scholar
  2. 2.
    Blaes F, Strittmatter M, Merkelbach S, Jost V, Klotz M, Schimrigk K, Hamann GF (1999) Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 246:299–303PubMedCrossRefGoogle Scholar
  3. 3.
    Counsell CE, McLeod M, Grant R (1994) Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 44:1184–1185PubMedGoogle Scholar
  4. 4.
    David YB, Warner E, Levitan M, Sutton DM, Malkin MG, Dalmau JO (1996) Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 78:2153–2156PubMedCrossRefGoogle Scholar
  5. 5.
    Esposito M, Penza P, Orefice G, Pagano A, Parente E, Abbadessa A, Bonavita V (2008) Successful treatment of paraneoplastic cerebellar degeneration with rituximab. J Neurooncol 86:363–364PubMedCrossRefGoogle Scholar
  6. 6.
    Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, Posner JB (1990) Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 322:1844–1851PubMedCrossRefGoogle Scholar
  7. 7.
    Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148PubMedCrossRefGoogle Scholar
  8. 8.
    Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, Delattre JY (2000) Treatment of paraneoplastic neurological syndromes with anti-neuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68:479–482PubMedCrossRefGoogle Scholar
  9. 9.
    Moll JW, Henzen-Logmans SC, Van der Meche FG, Vecht CH (1993) Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 56:112PubMedCrossRefGoogle Scholar
  10. 10.
    Phuphanich S, Brock C (2007) Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 81:67–69PubMedCrossRefGoogle Scholar
  11. 11.
    Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, Graus F (2003) Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 82:216–223Google Scholar
  12. 12.
    Shams’ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van ‘t Veer M, Sillevis Smitt P (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16–20PubMedCrossRefGoogle Scholar
  13. 13.
    Stark E, Wurster U, Patzold U, Sailer M, Haas J (1995) Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 52:814–818PubMedGoogle Scholar
  14. 14.
    Thone J, Hohaus A, Lamprecht S, Bickel A, Erbguth F (2008) Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci 272:171–173PubMedCrossRefGoogle Scholar
  15. 15.
    Uchuya M, Graus F, Vega F, Rene R, Delattre JY (1996) Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with anti-neuronal autoantibodies. J Neurol Neurosurg Psychiatry 60:388–392PubMedCrossRefGoogle Scholar
  16. 16.
    Vernino S, O’Neill BP, Marks RS, O’Fallon JR, Kimmel DW (2004) Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 6:55–62PubMedCrossRefGoogle Scholar
  17. 17.
    Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH (2003) Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 63:187–190PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • J. Schessl
    • 1
  • M. Schuberth
    • 1
  • P. Reilich
    • 1
  • P. Schneiderat
    • 1
  • N. Strigl-Pill
    • 1
  • M. C. Walter
    • 1
  • B. Schlotter-Weigel
    • 1
  • B. Schoser
    • 1
  1. 1.Department of Neurology, Friedrich-Baur-InstituteLudwig-Maximilians University of MunichMünchenGermany

Personalised recommendations